Tissue Regenix Completes Search For New CEO

Regenerative medicine firm Tissue Regenix has named Steve Couldwell as its new CEO, following the departure of Anthony Odell, who led the group for over a decade.

Regenerative medicine firm Tissue Regenix has named Steve Couldwell as its new CEO, following the departure of Anthony Odell, who led the group for over a decade. (Also see "Change At Helm As Tissue Regenix Enters Next Growth Phase" - Medtech Insight, 18 October, 2017.). Couldwell has been a non-executive director for the company since July 2013.

In October, Leeds, UK-based Tissue Regenix told Medtech Insight that Odell had stepped down with the agreement of the board of directors as the business moved into a new phase of development. Odell's departure came two months after he oversaw the closing of the acquisition of CellRight Technologies LLC(CRT), a Texas start-up specializing in bone regeneration

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Leadership

More from Medtech Insight

Mirvie Launches Predictive Blood Test For Preeclampsia

 
• By 

Mirvie launched Encompass, a blood test to help identify women over age 35 who are at moderate risk for preeclampsia, and will conduct additional studies to support reimbursements from payers.

Bringing Israeli Medical Device Candidates To The Right Partners In The US

 
• By 

Despite regional unrest, it is business as usual for medtech innovators and investors in Israel as evidenced by continued high-value M&A of locally developed technologies. Irit Yaniv, co-chair of the medtech session at the upcoming BioMed Israel 2025, explained the unique dynamics of Israeli medtech innovation.

How Structured Patient Engagement Gives Medtech Companies A Competitive Edge

 

Communication with patients has become a particularly crucial factor for investors, payers, and other healthcare decision-makers in a hostile market environment.